facebook linkedin twitter

Shkreli Ordered to Return $64M, is Barred from Drug Industry

January 15, 2022by Michael R. Sisak and Jennifer Peltz, Associated Press
Shkreli Ordered to Return $64M, is Barred from Drug Industry
Former Turing Pharmaceuticals CEO Martin Shkreli attends the House Committee on Oversight and Reform Committee hearing on Capitol Hill in Washington, Feb. 4, 2016. (AP Photo/Susan Walsh, File)

NEW YORK (AP) — Martin Shkreli must return $64.6 million in profits he and his former company reaped from jacking up the price and monopolizing the market for a lifesaving drug, a federal judge ruled Friday while also barring the provocative, imprisoned ex-CEO from the pharmaceutical industry for the rest of his life.

U.S. District Judge Denise Cote’s ruling came several weeks after a seven-day bench trial in December that featured recordings of conversations that Cote said showed Shkreli continuing to exert control over the company, Vyera Pharmaceuticals LLC, from behind bars and discussing ways to thwart generic versions of its lucrative drug, Daraprim.

“Shkreli was no side player in, or a ‘remote, unrelated’ beneficiary of Vyera’s scheme,” Cote wrote in a 135-page opinion. “He was the mastermind of its illegal conduct and the person principally responsible for it throughout the years.”

The Federal Trade Commission and seven states brought the case in 2020 against the man known in the media as “Pharma Bro,” about two years after he was sentenced to prison in an unrelated securities fraud scheme.


“‘Envy, greed, lust, and hate,’ don’t just ‘separate,’ but they obviously motivated Mr. Shkreli and his partner to illegally jack up the price of a life-saving drug as Americans’ lives hung in the balance,” New York Attorney General Letitia James said, peppering the written statement with references to the Wu-Tang Clan, whose one-of-a-kind album Shkreli had to fork over to satisfy court debt.

“But Americans can rest easy because Martin Shkreli is a pharma bro no more.”

Messages seeking comment were left with Shkreli’s lawyers.

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. It treats a rare parasitic disease that strikes pregnant women, cancer patients and AIDS patients.

Shkreli defended the decision as capitalism at work and said insurance and other programs ensured that people who need Daraprim would ultimately get it.

But the move sparked outrage from the medical community to Congress and was a rare source of bipartisan agreement on the 2016 presidential campaign trail, where Democrat Hillary Clinton called it price-gouging and future President Donald Trump, a Republican, called Shkreli “a spoiled brat.”


Shkreli eventually offered hospitals half off — still amounting to a 2,500% increase. But patients normally take most of the weekslong treatment after returning home, so they and their insurers still faced the $750-a-pill price.

Shkreli resigned as Turing’s CEO in 2015, a day after he was arrested on securities fraud charges related to two failed hedge funds he ran before getting into the pharmaceutical industry. He was convicted of lying to investors and cheating them out of millions and is serving a seven-year sentence at a federal prison in Allenwood, Pennsylvania, and is due to be released in November.

The FTC and seven states — New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia — alleged in their case that Vyera hiked the price of Daraprim and illegally created “a web of anticompetitive restrictions” to prevent other companies from creating cheaper generic versions. Among other things, they alleged, Vyera blocked access to a key ingredient for the medication and to data the companies would want to evaluate the drug’s market potential.

Vyera and its parent company, Phoenixus AG, settled last month, agreeing to provide up to $40 million in relief over 10 years to consumers and to make Daraprim available to any potential generic competitor at the cost of producing the drug. Former Vyera CEO Kevin Mulleady agreed to pay $250,000 if he violates the settlement, which barred him from working for a pharmaceutical company” for seven years.

Shkreli proceeded to trial but opted not to attend the proceedings, instead submitting a written affidavit that served as his testimony.

The trial record included evidence showing Shkreli kept in regular contact with company executives, even after he went to prison. A spreadsheet kept by one executive showed more than 1,500 contacts with Shkreli between December 2019 and July 2020.

The record also included recordings of conversations Shkreli had from prison in which he discussed his control of Vyera, saying he had “no problem firing everybody,” boasting how he controlled the board, and comparing himself to Facebook founder Mark Zuckerberg and the pharmaceutical company to the social media behemoth.

Zuckerberg “just happens to own the thing, and that’s the way it is,” Shkreli said in one of the recordings. You “can’t go in there and tell Zuckerberg what to do.”


In 2019, Shkreli was sent to solitary confinement for a time after prison officials discovered him using a contraband smartphone to conduct business.

“Whether he used a smuggled phone or the prison’s authorized phones, he stayed in touch with Vyera’s management and exercised his power over Vyera as its largest shareholder,” Cote wrote.

A+
a-

In The News

Health

Voting

Prescription Drugs

April 27, 2022
by Tom Ramstack
Lawmakers Say Consulting Firm Marketing Contributed to Half-Million Opioid Deaths

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the... Read More

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the opioid epidemic that has killed more than a half-million Americans. A McKinsey & Co. official admitted to earning at least $86 million for helping pharmaceutical companies... Read More

April 19, 2022
by Dan McCue
Supreme Court Seeks Solicitor General Input on Biologic Drug Patents

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent... Read More

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent case the outcome of which could ultimately be worth billions of dollars. The case, Amgen v. Sanofi, emanates from the U.S. District Court for the Federal... Read More

House Passes $35-a-Month Insulin Cap as Dems Seek Wider Bill

WASHINGTON (AP) — The House has passed a bill capping the monthly cost of insulin at $35 for insured patients,... Read More

WASHINGTON (AP) — The House has passed a bill capping the monthly cost of insulin at $35 for insured patients, part of an election-year push by Democrats for price curbs on prescription drugs at a time of rising inflation. Experts say the legislation, which passed 232-193... Read More

March 30, 2022
by Dan McCue
House to Vote on Insulin Price Reduction Bill Thursday

WASHINGTON — The House on Thursday is expected to vote to cap the out-of-pocket cost of insulin for consumers at... Read More

WASHINGTON — The House on Thursday is expected to vote to cap the out-of-pocket cost of insulin for consumers at $35 per month. If also passed by the Senate, which is expected to vote the measure up by Easter, the long-awaited reform will go into effect... Read More

March 19, 2022
by TWN
Congressional Panel Takes Deep Dive Into Future of FDA’s Accelerated Approvals

WASHINGTON — The House Energy and Commerce Subcommittee on Health panel Thursday spent the majority of their time considering the... Read More

WASHINGTON — The House Energy and Commerce Subcommittee on Health panel Thursday spent the majority of their time considering the future of the Food and Drug Administration's so-called Accelerated Approval Program. A number of the 20 different health care-related bills discussed by the subcommittee figure in... Read More

March 19, 2022
by TWN
CMS Decision to Limit Coverage of Alzheimer’s Treatment Takes Center Stage

WASHINGTON — A House panel scheduled to kick the tires on roughly 20 different health care-related bills on Thursday spent... Read More

WASHINGTON — A House panel scheduled to kick the tires on roughly 20 different health care-related bills on Thursday spent time considering the Food and Drug Administration’s decision to grant accelerated approval to the first disease-modifying treatment for Alzheimer’s disease and the Centers for Medicare and... Read More

News From The Well
scroll top